Ivemend is a medicine for preventing nausea (feeling sick) and vomiting caused by chemotherapy cancer medicines. It is used in adults and children from 6 months of age who are undergoing chemotherapy known to cause moderate or severe nausea and vomiting. It contains the active substance fosaprepitant.
Therapeutic Indication
### Therapeutic indication Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and paediatric patients aged 6 months and older. Ivemend 150 mg is given as part of a combination therapy.
Therapeutic Area (MeSH)
ATC Code
A04AD12
ATC Item
aprepitant
Pharmacotherapeutic Group
Antiemetics and antinauseants
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| fosaprepitant | N/A | 福沙匹坦双葡甲胺 |
EMA Name
Ivemend
Medicine Name
Ivemend
Aliases
N/ANo risk management plan link.
